CD1D and neoplasm: Again, treatment with CD1d-Vδ2 hu-bsTCE (2 mg kg−1) alone had no effect, and PBMCs alone or combined with control gp120-Vδ2 bsTCE administration slightly reduced tumor growth, resulting in a minor increase in survival (median 26, 26, 31, and 29 days, respectively) (Figure 6D).